Truist Financial Raises Centessa Pharmaceuticals (NASDAQ:CNTA) Price Target to $38.00

Centessa Pharmaceuticals (NASDAQ:CNTA) had its target price increased by analysts at Truist Financial from $33.00 to $38.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price target points to a potential upside of 54.66% from the stock’s previous close.

Several other equities research analysts have also issued reports on CNTA. B. Riley lifted their price target on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Wells Fargo & Company boosted their target price on Centessa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. TD Cowen restated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Piper Sandler restated an “overweight” rating on shares of Centessa Pharmaceuticals in a research report on Friday, January 16th. Finally, Chardan Capital reiterated a “buy” rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, January 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Centessa Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

Centessa Pharmaceuticals Stock Down 1.3%

CNTA opened at $24.57 on Thursday. The firm has a market capitalization of $3.30 billion, a P/E ratio of -13.43 and a beta of 1.56. Centessa Pharmaceuticals has a one year low of $9.60 and a one year high of $30.58. The company has a fifty day moving average price of $25.56 and a 200-day moving average price of $22.37. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02). Equities research analysts expect that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, CTO Tia L. Bush sold 40,000 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the transaction, the chief technology officer directly owned 121,503 shares of the company’s stock, valued at approximately $3,159,078. The trade was a 24.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mario Alberto Accardi sold 10,000 shares of the company’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the completion of the transaction, the insider owned 178,801 shares of the company’s stock, valued at $5,364,030. This trade represents a 5.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.09% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. TD Waterhouse Canada Inc. purchased a new stake in Centessa Pharmaceuticals in the fourth quarter worth about $25,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Centessa Pharmaceuticals by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock valued at $117,000 after purchasing an additional 979 shares during the period. DNB Asset Management AS bought a new stake in shares of Centessa Pharmaceuticals during the third quarter valued at approximately $218,000. Sigma Planning Corp purchased a new stake in Centessa Pharmaceuticals in the fourth quarter worth $225,000. Finally, Campbell & CO Investment Adviser LLC bought a new position in Centessa Pharmaceuticals in the second quarter worth $218,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.